Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | CASP7 | P55210 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30170473 | 1.00 | MAOA (0.52) | MAOAMAOBALDH1A1KDM4EAPP | |
| Benzoylenurea SCHEMBL1752723 | 0.77 | KDM4E (0.45) | MAOAMAOBALDH1A1KDM4EHPGD | |
| Benzoylenurea SCHEMBL29460047 | 0.77 | KDM4E (0.45) | MAOAMAOBALDH1A1KDM4EHPGD | |
| SCHEMBL29389300 | 0.77 | MAOA (0.56) | MAOAMAOBALDH1A1KDM4EAPP | |
| SCHEMBL92707 | 0.77 | MAOA (0.56) | MAOAMAOBALDH1A1KDM4EAPP | |
| Bicarbonate SCHEMBL11023181 | 0.75 | MAOA (0.48) | MAOAMAOBALDH1A1KDM4EAPP | |
| SCHEMBL8361293 | 0.75 | ALDH1A1 (0.42) | ALDH1A1KDM4EHPGDTDP1CASP7 | |
| SCHEMBL7607540 | 0.75 | GPR3 (0.54) | MAOAMAOBALDH1A1KDM4EHPGD | |
| SCHEMBL4681829 | 0.74 | GPR3 (0.59) | MAOAMAOBALDH1A1KDM4EAPP | |
| SCHEMBL17508358 | 0.74 | MAOA (0.52) | MAOAMAOBALDH1A1KDM4EAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722198-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL DISEASES AND INFECTIONS | Technische Universität München, in Vertretung des Freistaats Bayern (DE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4125912-B1 | COMPOUNDS FOR THE IN VITRO INHIBITION OF THE RNA-DEPENDENT RNA POLYMERASE OF CORONAVIRUSES | R G C C HOLDINGS AG (CH) | 2025-07-30 | — | — | EP | disclosed |
| EP-4125912-A1 | NUCLEOTIDE ANALOGUES FOR THE TREATMENT OF CORONAVIRUSES | R.G.C.C. Holdings AG (CH) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021191236-A1 | NUCLEOTIDE ANALOGUES FOR THE TREATMENT OF CORONAVIRUSES | R.G.C.C. Holdings AG (CH) | 2021-09-30 | — | — | WO | disclosed |
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | ABBVIE INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3056207-B1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMA CO LTD (JP) | 2018-06-20 | — | — | EP | disclosed |
| EP-2867221-B1 | CYANOGUANIDINES AND THEIR SUE AS ANTIVIRAL AGENTS. | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3252045-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-0669919-B1 | USE OF DIMETHYLBENZOFURANS AND DIMETHYLBENZOPYRANS AS 5-HT3 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 1999-01-27 | — | — | EP | disclosed |
| US-5863923-A | TREATMENT OF ANXIETY, PSYCHOSIS, SCHIZOPHRENIA, DRUG ABUSE, IRRITABLE BOWEL SYNDROME | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-26 | — | — | US | disclosed |
| EP-0885190-A1 | NOVEL N-SUBSTITUTED 4-((4'-AMINOBENZOYL)-OXYMETHYL)-PIPERIDINES HAVING GASTRIC PROKINETIC PROPERTIES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-23 | — | — | EP | disclosed |
| US-5674868-A | ADMINISTERING TO TREAT DISORDERS SUCH AS ANXIETY, PSYCHOSIS, DEPRESSION, SCHIZOPHRENIA, DURG ABUSE, MIGRAINE, EMESIS AND IRRITABLE BOWEL SYNDROME | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-10-07 | — | — | US | disclosed |
| WO-1997031897-A1 | NOVEL N-SUBSTITUTED 4-((4'-AMINOBENZOYL)-OXYMETHYL)-PIPERIDINES HAVING GASTRIC PROKINETIC PROPERTIES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-09-04 | — | — | WO | disclosed |
| EP-0669919-A1 | USE OF DIMETHYLBENZOFURANS AND DIMETHYLBENZOPYRANS AS 5-HT3 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994012494-A1 | USE OF DIMETHYLBENZOFURANS AND DIMETHYLBENZOPYRANS AS 5-HT3 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-06-09 | — | — | WO | disclosed |
| EP-0034529-B1 | TRIAZOLOQUINAZOLINONE DERIVATIVES AND THEIR ACID ADDITION SALTS, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1983-07-20 | — | — | EP | disclosed |
| US-4350695-A | Antihistaminic and bronchospasmolytic triazoloquinazolinones | ROUSSEL UCLAF (FR) | 1982-09-21 | — | — | US | disclosed |
| EP-0034529-A1 | Triazoloquinazolinone derivatives and their acid addition salts, their preparation, their use as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | RNGTT, GMPS, RNMT | MAOA 882/4885MAOB 506/4885ALDH1A1 4019/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | MAOA 349/4885MAOB 232/4885ALDH1A1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.